Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent PlasmaHyung Park, Eva Petkova, Prasun Bhattacharya et al.|JAMA Network Open|2022Cited by 66
Dual Affinity to RBCs and Target Cells (DART) Enhances Both Organ- and Cell Type-Targeting of Intravascular NanocarriersLaura T. Ferguson, Elizabeth D. Hood, Tea Shuvaeva et al.|ACS Nano|2022Cited by 56
Targeted Nanocarriers Co-Opting Pulmonary Intravascular Leukocytes for Drug Delivery to the Injured BrainJia Nong, Oscar A. Marcos‐Contreras, Patrick M. Glassman et al.|ACS Nano|2023Cited by 28
Early administration of <scp>COVID</scp>‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacyArtur Belov, Peter Marks, Yin Huang et al.|American Journal of Hematology|2022Cited by 21
FDA Review of Investigational Use of COVID-19 Convalescent PlasmaSalim El Haddad, Nicole Verdun, Victor C. Baum et al.|Unknown|2020Cited by 6